Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Climb Bio ( (CLYM) ) has issued an announcement.
On September 29, 2025, Climb Bio announced new preclinical data for CLYM116, a monoclonal antibody targeting APRIL, showing improved pharmacokinetics and pharmacodynamics compared to sibeprenlimab. The data demonstrated deeper IgA reduction and a longer half-life, suggesting potential for less frequent dosing in IgA nephropathy treatment. Climb Bio plans to initiate a Phase 1 trial for CLYM116 in the fourth quarter of 2025, with initial data expected by mid-2026. The company aims to capitalize on the IgAN market, estimated at $10-20 billion in the US, by addressing the need for more active management as highlighted in the updated KDIGO guidelines.
The most recent analyst rating on (CLYM) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Climb Bio stock, see the CLYM Stock Forecast page.
Spark’s Take on CLYM Stock
According to Spark, TipRanks’ AI Analyst, CLYM is a Neutral.
Climb Bio’s stock score is primarily driven by its financial performance, reflecting the company’s developmental challenges with negative income and cash flow. Despite strong equity and cash reserves, the technical indicators show a bearish trend, and the valuation reflects typical early-stage biotech characteristics with a negative P/E ratio. The absence of significant earnings call data or corporate events means the focus remains on financial stability and potential for future growth.
To see Spark’s full report on CLYM stock, click here.
More about Climb Bio
Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases. The company’s pipeline includes CLYM116, an anti-APRIL monoclonal antibody in development for IgA nephropathy, and budoprutug, an anti-CD19 monoclonal antibody targeting B-cell mediated diseases.
Average Trading Volume: 493,520
Technical Sentiment Signal: Hold
Current Market Cap: $144.3M
Find detailed analytics on CLYM stock on TipRanks’ Stock Analysis page.